Author: K. John Morrow, Jr. Ph.D.
Table 1.1. A Wide Range of Species Under Study for Protein Production
Table 2.1. Selected List of Approved Recombinant Therapeutic Proteins Produced in Mammalian Cell Lines (Messi 2009, See Appendix)
Table 2.2. Mammalian Cell Culture Products and Media
Table 2.3. Recommendations by Regulatory Agencies and Physicians‘ Organizations for the Avoidance of Human or Animal Proteins in Drug Manufacturing
Table 2.4. Approved Therapeutic Protein-Based Products from E. coli.
Table 2.5. Comparison of Plants Built to Accommodate Reusable Versus Disposable Upstream Bioprocessing Facilities
Table 3.1. Various Polishing Options
Table 3.2. Typical Platform for MAb Purification
Table 3.3. Companies Dealing with Liquid Chromatography Systems and Products
Table 4.1. FDA Biologics Approvals, 2009
Table 6.1. Comparative Salaries (in US $$) for High-Tech Occupations in Various Countries, 2008
Figure 2.1. Number (and Percentage Values Siding the Bars) of Recombinant Proteins Approved as Biopharmaceuticals in Different Production Systems*
Figure 2.2. General Scheme for Commercial Development and Production of a Plasma-Free Recombinant Therapeutic Protein. In Every Step of the Manufacturing Process, Animal- or Human-Derived Additives Are Replaced by Plant-Based or Synthetic Moleculesa).
Figure 6.1. Cell-Free Synthesis Production Example